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Abstract
Introduction: The incidence of left ventricular (LV) thrombus formation in ST-segment elevation myocardial infarction
(STEMI) patients in the current era of primary percutaneous coronary intervention (PCI) is not well established. We
performed a meta-analysis to assess the actual incidence and predictors of LV thrombus by cardiovascular magnetic
resonance (CMR) in STEMI treated by primary PCI.
Methods: We searched MEDLINE and EMBASE databases up to February 2018. We included all studies published as
a full-text article, reporting the incidence of LV thrombus by CMR within 1 month following acute STEMI in patients
treated by primary PCI. A binary random-effects model was used to estimate the pooled incidence of LV thrombus.
The diagnostic performance of transthoracic echocardiography (TTE) as compared with CMR was pooled to obtain the
sensitivity and specificity of TTE with CMR as the gold standard. Embolic and bleeding complications of LV thrombus
were also evaluated.
Results: Ten studies were included in the meta-analysis. The incidence of LV thrombus by CMR in all-comer STEMI
patients (n = 2072) was 6.3% with 96% of LV thrombus occurring in those with anterior STEMI (12.2% incidence). When
only anterior STEMI with LVEF< 50% were considered (n = 447), the incidence of LV thrombus was 19.2%. Compared
with CMR, the sensitivity of TTE to detect LV thrombus was 29% with a specificity of 98%. The sensitivity of TTE
increased to 70% in those with anterior STEMI and reduced LVEF. LV thrombus resolved in 88% of cases by 3 to
6 months. After 1–2 years follow-up, the embolic complication rate was similar at 1.5% (P = 0.25) but the bleeding
complication rate was significantly higher (8.8% versus 0.5%, P < 0.001) in the LV thrombus group on triple therapy when
compared to the no LV thrombus group on dual antiplatelet therapy.
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Conclusion: In the primary PCI era, CMR detection of an LV thrombus post-STEMI remains high with incidence of nearly
20% in anterior STEMI with depressed LVEF. Patients with LV thrombus treated by triple therapy had similar embolic
complications but higher bleeding complications than those with no LV thrombus treated with dual antiplatelet therapy.
A 3 month follow-up CMR scan to guide anticoagulation duration might help mitigate bleeding risk.
Keywords: Left ventricular thrombus, ST-segment elevation myocardial infarction, Cardiovascular magnetic resonance,
Primary percutaneous coronary intervention
Background
Primary percutaneous coronary intervention (PCI) is
the reperfusion strategy of choice for the treatment of
ST-segment elevation myocardial infarction (STEMI).
Although left ventricular (LV) thrombus formation is a
recognized complication in STEMI patients, its inci-
dence in the era of primary PCI is not well established.
LV thrombus may lead to embolic complications such
as stroke, with devastating consequences. Both the
American College of Cardiology/American Heart Asso-
ciation/and European Society of Cardiology guidelines
[1, 2] recommend a minimum of 3 to 6 months of
anticoagulation (Class IIb and IIa respectively, level of
evidence C) with subsequent repeated imaging to guide
ongoing anticoagulation.
A meta-analysis recently reported that the ovrall rate
of LV thrombus by transthoracic echocardiography
(TTE) in the primary PCI for STEMI era was 2.7% with
9.1% for anterior STEMI [3]. However, TTE has a lower
sensitivity (35%) for detecting LV thrombus when com-
pared to cardiovascular magnetic resonance (CMR) [4].
However, TTE relies on the morphological identification
of LV thrombus, whereas CMR with gadolinium contrast
agent can identify LV thrombus based on both its
morphology and tissue characteristics [4].
We therefore performed a meta-analysis to assess the
incidence and predictors of LV thrombus by CMR in
STEMI patients treated by primary PCI in the current
era and to evaluate how it may be used in the clinical
setting, in conjunction with TTE, to improve LV
thrombus detection.
Methods
This meta-analysis adhered to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [5] and was performed according
to the recommendations specified in the Cochrane
Handbook for Systematic Reviews of Interventions [6].
Eligibility criteria
All studies reporting on the incidence of LV thrombus
by CMR in STEMI patients treated by primary PCI were
eligible for inclusion. The inclusion criteria were all
studies published as a full-text article reporting the
CMR incidence of LV thrombus within 1 month follow-
ing acute STEMI in patients treated by primary PCI.
Conference abstracts were excluded.
Search strategy
We searched Ovid MEDLINE and Ovid EMBASE data-
bases up to February 2018. Furthermore, we screened
editorials and references of eligible studies. The follow-
ing search terms were used: “ventricular”, “apical”,
“thrombus”, “magnetic resonance imaging”, “acute myo-
cardial infarction”, “primary percutaneous intervention”.
Study selection
Two authors (HB, MHHC) identified suitable articles in-
dependently. Disagreement was resolved through con-
sensus from a third investigator (DJH). Figure 1 shows
the process of study selection as per PRISMA [5].
Data extraction and quality assessment
Baseline clinical characteristics of the study population
were extracted. Trial quality was determined as per the
Cochrane Handbook [6] but without constructing a
composite quality score given the limitations inherent
to such an approach [7]. We aimed to produce a funnel
plot if there were > 10 included studies in the forest
plots.
Endpoints
The main endpoints analyzed were incidence of LV
thrombus identified on the acute CMR and follow-up
CMR when available. Furthermore, the incidences of em-
bolic and bleeding complications as defined by the indi-
vidual studies were also collected.
Statistical analysis
The studies were divided into those including
all-comer STEMI, anterior STEMI patients and those
with anterior STEMI and with reduced LV ejection
fraction (LVEF). A binary random-effects model was
used to estimate the pooled incidence of LV thrombus
with 95% confidence interval (CI) using OpenMeta[A-
nalyst] [8] software. Where available, studies
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comparing the diagnostic performance of TTE versus
CMR were pooled to obtain the sensitivity and specifi-
city of TTE against CMR. Lastly, embolic complica-
tions (ischemic stroke and clinically significant
peripheral embolisation) and bleeding complications
between those with LV thrombus against those without
LV thrombus were also compared. Heterogeneity
among the studies included in each forest plot was
quantified using I2 statistics with I2 of 0–25%, 25–50%
and 50–75% considered as low, moderate and high het-
erogeneity, respectively.
Results
Ten studies [4, 9–17] were included in the meta-analysis.
The characteristics of these studies are summarized in
Table 1. The CMR scan was performed within the first
week post-primary PCI in 7 studies [10–16], and between
7 and 30 days in 3 studies [4, 9, 17].
Incidence of LV thrombus
Six studies [4, 10–14] included data on LV thrombus in
anterior versus non-anterior STEMI. The overall inci-
dence of LV thrombus in STEMI patients (n = 2072) was
6.3% (95%CI 4.2–8.5), I2 of 72% (Fig. 2) with 96% (111/
116) of thrombi occurring with anterior STEMI. Among
those with anterior STEMI only (7 studies, n = 1244) [4,
9–14], the incidence of LV thrombus was 12.2% (95%CI
9.0–15.4%), I2 = 64%, (Fig. 2).
Sensitivity analysis was performed by excluding the
studies by Poss 2015 [10] and Lanzillo 2013 [11] (outliers
on the Forest plot in Fig. 1). The overall incidence of LV
thrombus was similar at 6.5% (95%CI 5.0–7.9%) STEMI
Fig. 1 PRISMA flow diagram of the study selection process. This is the PRISMA flow diagram showing how studies were identified, screening and
included in this meta-analysis
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(n = 1298) and was 12.8% (95%CI 10.6–15.0%) for anterior
STEMI (n = 886), with I2 of 9% and 0%, respectively.
Three studies [15–17] included only patients with
LVEF < 40–45%. One study [13] also reported the inci-
dence of LV thrombus in those with anterior STEMI
and LVEF< 50%. When only anterior STEMI with re-
duced LVEF were considered, the pooled incidence of
LV thrombus in the 447 patients was 19.2% (95%CI 7.7–
30.8%), I2 = 90%.
Three studies (acute CMR performed within the first
week) also had a repeat CMR between 3 to 6 months [12–
14]. LV thrombus resolved in 88% (50/57) of cases. However,
late LV thrombus was detected in an additional 3.2% (95%CI
1.4–5.1%) of cases (29/868) on the 3 to 6 months CMR.
Sensitivity and specificity of TTE against CMR
Three studies [4, 11, 12] presented data on LV thrombus
detection by both TTE and CMR. Among the 431 patients
with both CMR and TTE data, using CMR as the reference
standard, the sensitivity of TTE was only 29% (95%CI 17–
45%) with a specificity of 98% (95%CI 96–99%).
For anterior STEMI with reduced LVEF, 3 studies also
presented data on the detection of LV thrombus by both
TTE and CMR. For the 246 patients, the sensitivity of
TTE for LV thrombus was 70% (95%CI 56–82%) with a
specificity of 98% (95%CI 94–99%).
Embolic and bleeding complications
Three studies [12, 13, 17] reported embolic and bleeding
complications separately. All patients with LV thrombus
were started on triple therapy (anticoagulation together
with dual antiplatelet therapy).
After a follow-up period of between 1 and 2 years, the
incidence of embolic complications (ischemic stroke and
distal embolisation) was similar at 1.5% in both the LV
thrombus group (1/68) on triple therapy (anticoagula-
tion plus dual antiplatelet therapy) and no LV thrombus
group (9/616) on dual antiplatelet therapy only, P = 0.25,
I2 = 0%. However, bleeding complications were signifi-
cantly higher in the LV thrombus group (6/68, 8.8%)
than in the no LV thrombus group (3/616, 0.5%), P <
0.001, I2 = 65%.
Fig. 2 Forest plot of incidence of left ventricular (LV) thrombus by cardiovascular magnetic resonance (CMR) in ST elevation myocardial infarction
(STEMI) patients treated by primary percutaneous coronary intervention (PCI). Forest plot showing the overall incidence of LV thrombus in STEMI
and those with an anterior STEMI
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Discussion
In this meta-analysis of more than 2000 patients, overall
CMR evidence of LV thrombus was > 6% of primary PCI
STEMI patients. This is more than twice that reported
by TTE [3]. We also confirmed that TTE had a poor
sensitivity of only 29% when compared to CMR. The
strength of CMR lies in its spatial resolution for mor-
phological definition of the LV thrombus. Avascular
thrombus can also be characterized and differentiated
from neighbouring structures using gadolinium chelate
contrast as illustrated in Fig. 3.
Expectedly, the large majority (96%) of LV thrombus
by CMR occurred in those with anterior STEMI. The in-
cidence of LV thrombus in anterior STEMI was more
than 12%. In the subgroup of patients with anterior
STEMI and LVEF< 50%, LV thrombus by CMR was de-
tected in a remarkably high proportion of patients: one
in five patients. Of note, the sensitivity of TTE was
higher at 70% in this subgroup of patients.
The incidence of LV thrombus in the study Poss 2015
[10] was lowest (3.5%), despite including the largest
number of patients (n = 738). This may be related to the
early use of the potent glycoprotein IIb/IIIa inhibitor
abciximab (intracoronary or intravenous) and warrants
further investigation.
The incidence of LV thrombus by CMR is dependent on
the timing of the CMR scan. An additional 3% of patients
were identified to have late LV thrombus of the CMR per-
formed between 3 and 6 months. Gellen et al. [9] recently
showed that the highest LV thrombus detection rate (25%)
was in those with CMR performed 9–12 days after anter-
ior STEMI and Meurin et al. [17] showed a similar finding
with those having the CMR scan between 8 and 15 days
having the higher incidence of LV thrombus. These data
suggest that the optimal timing of imaging for LV
thrombus following an acute STEMI may be at 2 weeks.
Consistent with prior studies, risk factors for LV
thrombus formation were anterior STEMI and LVEF<
50% [10, 13]. The presence of microvascular obstruction
(MVO) [10] and apical wall motion abnormality [4] has
also been associated with the development of LV
thrombus. It has also recently been shown that LV
thrombus was associated with a composite of heart fail-
ure, re-infarction and mortality [10]. This is likely a re-
flection of those with LV thrombus having larger infarct
size, higher burden of MVO and lower LVEF.
Although the number of studies was limited, accounting
for 684 patients, the incidence of embolic complications in
those with LV thrombus and treated by anticoagulation
was similar to those without LV thrombus. However, as ex-
pected, those with LV thrombus and triple therapy had
higher incidence of bleeding complications. The large pro-
portion of LV thrombus (88%) resolved on the repeat CMR
performed between 3 to 6 months. A follow-up CMR scan
as early as 3 months after STEMI may reduce the need for
prolonged anticoagulation in a proportion of patients.
LV thrombus post acute STEMI is well recognised to
occur predominantly at the apex [4] and in those with
reduced LVEF [13]. The likely explanation why the inci-
dence of LV thrombus is higher in anterior STEMI is
likely because the left anterior descending artery sub-
tends the largest amount of myocardium compared with
the left circumflex coronary artery and right coronary ar-
tery and the left anterior descending artery wraps
around the apex in three quarter of cases [18]. Moreover,
a large anterior STEMI involving the apex would lead to
blood stasis and endothelial injury, pre-requisites for the
development of LV thrombus [19]. Despite the low sen-
sitivity of TTE, it is more widely available and more af-
fordable than CMR. Apical wall motion score has been
shown to be useful to identify those would benefit from
CMR imaging for LV thrombus detection. Therefore, we
propose an algorithm, starting from the time of primary
PCI that may be used to identify those most likely to de-
velop LV thrombus and who may benefit from CMR if
TTE is inconclusive (Fig. 4).
Fig. 3 Early post-contrast CMR images of LV thrombus from 3 patients with acute STEMI treated by primary PCI. These 4-chamber views from 3
different patients illustrate LV thrombus of different sizes (red arrow) identified from the early post-contrast images acquired at high inversion
time to null the avascular thrombus and MVO as black
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LV thrombus can sometimes be difficult to distinguish
from MVO. The following previously described criteria [20]
can be applied to differentiate between the two on late
gadolinium enhanced images: location (LV thrombus tends
to be intra-cavity whereas MVO is intra-myocardial);
contrast fill-in on subsequent late gadolinium enhanced im-
ages would occur in the context of MVO but not with LV
thrombus; differences in appearance (LV thrombus is usu-
ally well-defined with sharp borders whereas MVO tends
to be patchy and inhomogeneous) as shown in Fig. 5.
Fig. 4 Algorithm for the detection of LV thrombus in reperfused STEMI patients in the clinical setting. This algorithm provides guidance on how
STEMI patients at risk could be identified and how TTE and CMR could be integrated in the clinical setting to optimize the detection of LV thrombus
Fig. 5 Differences in appearance between LV thrombus and microvascular obstruction (MVO). These are the early and late post-contrast short-axis
images from a patient with LV thrombus and MVO. The red arrows show the LV thrombus and the blue arrows delineate the MVO
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Contrast TTE has also been used for the detection of LV
thrombus with an improved sensitivity of 64% when com-
pared to CMR [4]. This suggests that CMR may still be
useful in high risk patients despite a negative contrast TTE.
In the chronic MI setting, in a cohort of patients with is-
chemic heart disease undergoing assessment for LV re-
construction surgery, the sensitivity of CMR against the
pathological confirmation of LV thrombus was high at
88% [21]. The sensitivity of non-simultaneous TTE in that
study was as low as 23% and that of intraoperative trans-
esophageal echocardiography was only 40% [21]. The find-
ing from our study is in line with this previous study
showing a poor sensitivity of TTE to detect LV thrombus.
Limitations
The techniques used in this meta-analysis to detect LV
thrombus by TTE did not include echo contrast or
newer 3D volumetric methods. The techniques used to
detect LV thrombus by CMR (first-pass perfusion [14],
conventional late gadolinium enhancement [9–13] or
long inversion time gadolinium enhancement imaging
[4]) and the timing of CMR in relation to the primary
PCI were not standardized in the included studies. The
studies were included in the forest plots showed high
heterogeneity but we performed sensitivity analysis and
this showed consistent results while improving the I2
significantly. Several of the secondary analyses included
data from only 3 studies, but these constituted the lar-
gest pooled analyses and need to be confirmed in future
larger prospective studies. Patient-level data were not
available. Despite these limitations, our study provides a
more accurate estimate of the true incidence of LV
thrombus from a pooled analysis of > 2000 STEMI pa-
tients in the current primary PCI era. However, a pro-
portion of STEMI patients with LV thrombus currently
go undetected, as CMR is not part of routine practice.
The natural history of these patients, especially in the
current era of potent antiplatelet therapy is not known
and could not be answered by this study. Lastly, CMR is
currently not widely available, is relatively expensive and
there may be an element of selection bias (only patients
fit enough to lie flat, with no contraindications would
tolerate the scan).
Conclusion
CMR is a valuable tool for the detection of LV thrombus
post-primary PCI for acute STEMI and the incidence re-
mains clinically substantial at 6% of all-comers STEMI,
12% of anterior STEMI and 19% of anterior STEMI pa-
tients with reduced LVEF. We propose that CMR may
have a role in high-risk STEMI patients (akinetic apex)
and in patients with inconclusive TTE. Patients with LV
thrombus treated with triple therapy (anticoagulation and
dual antiplatelet therapy) have similar embolic complica-
tion rates but higher bleeding complication rates as com-
pared with those with no LV thrombus treated with dual
antiplatelet therapy only. We suggest a repeat CMR scan
at 3 months post-STEMI to guide anticoagulation dur-
ation and to potentially reduce bleeding risk.
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